Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207374 | 0.71 | HAO1 (0.45) | ALDH1A1MAPTKDM4ENOTUMKMT2A | |
| SCHEMBL2282611 | 0.71 | POLB (0.56) | EGFRLCKALDH1A1MAPTKDM4E | |
| SCHEMBL29543630 | 0.71 | POLB (0.56) | EGFRLCKALDH1A1MAPTKDM4E | |
| SCHEMBL30688805 | 0.71 | POLB (0.56) | EGFRLCKALDH1A1MAPTKDM4E | |
| SCHEMBL6206688 | 0.70 | ALDH1A1 (0.41) | ALDH1A1MAPTKDM4EHPGDNOTUM | |
| SCHEMBL4453848 | 0.70 | MCL1 (0.40) | ALDH1A1MAPTKDM4EHPGDKMT2A | |
| SCHEMBL10596007 | 0.69 | POLB (0.55) | EGFRLCKALDH1A1MAPTKDM4E | |
| SCHEMBL27451779 | 0.69 | NOTUM (0.48) | EGFRLCKALDH1A1MAPTKDM4E | |
| SCHEMBL24628306 | 0.69 | IDO1 (0.48) | EGFRLCKALDH1A1MAPTKDM4E | |
| SCHEMBL11816219 | 0.68 | POLB (0.59) | ALDH1A1MAPTKDM4EHPGDNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236720-B1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6872722-B2 | Therapies for tissue damage resulting from ischemia | PFIZER INC (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1260224-B1 | Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage | PFIZER PROD INC (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | MYLARI BANAVARA L (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | PFIZER INC | 2004-10-07 | — | — | US | disclosed |
| US-6730674-B2 | ANTIDIABETIC AGENTS | PFIZER INC | 2004-05-04 | — | — | US | disclosed |
| EP-1392310-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | Pfizer Products Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030008871-A1 | Therapies for tissue damage resulting from ischemia | MYLARI BANAVARA L (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | MARTIN WILLIAM H (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1260224-A1 | Sulfonyl pyridazinone compounds as therapeutic agents for ischemic tissue damage | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002087584-A1 | COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| EP-1236720-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | Pfizer Products Inc. (US) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004124-A1 | THERAPIES RELATING TO COMBINATIONS OF ALDOSE REDUCTASE INHIBITORS AND CYCLOOXYGENASE-2 INHIBITORS | ALDOA, AKR1B1, ALDH2 | EGFR 4673/4885LCK 2586/4885ALDH1A1 30/4885 |
| US-20040198740-A1 | Therapies relating to combinations of aldose reductase inhibitors and cyclooxygenase-2 | ALDOA, ALDH2, AKR1B1 | EGFR 4691/4885LCK 2687/4885ALDH1A1 30/4885 |
| US-20030008871-A1 | Therapies for tissue damage resulting from ischemia | TNNI3, TNNC1, TNNT2 | EGFR 2803/4885LCK 1228/4885ALDH1A1 242/4885 |
| US-20030004139-A1 | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | ALDOA, PDXK, AKR1B1 | EGFR 4544/4885LCK 4013/4885ALDH1A1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.